Ovid Therapeutics (OVID) Liabilities and Shareholders Equity (2016 - 2026)

Ovid Therapeutics has reported Liabilities and Shareholders Equity for 11 years, with the latest figure at $225.6 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 176.32% year-over-year to $225.6 million; the trailing twelve-month figure through Mar 2026 stood at $517.8 million (up 31.24% YoY), and the FY2025 full-year result was $150.9 million, up 63.76% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $225.6 million, up from $150.9 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $225.6 million in Q1 2026, with the low at $63.8 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $134.2 million across 5 years, with a median of $136.2 million in 2023.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity slumped 37.96% — and 2026, when it jumped 176.32%.
• Ovid Therapeutics' Liabilities and Shareholders Equity stood at $155.3 million in 2022, then decreased by 7.24% to $144.0 million in 2023, then tumbled by 36.01% to $92.2 million in 2024, then jumped by 63.76% to $150.9 million in 2025, then surged by 49.49% to $225.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $225.6 million (Q1 2026), $150.9 million (Q4 2025), and $63.8 million (Q3 2025), per Business Quant data.